American Association for Cancer Research^® (AACR) Annual Meeting 2026
Not affiliated with or endorsed by AACR.

April 19-22, 2026, San Diego, California

This meeting is the epicenter of progress in the fight against cancer, where scientists, clinicians, healthcare professionals, survivors, and advocates come together to share groundbreaking research. From innovative population science and prevention to cutting-edge cancer biology, translational studies, and clinical breakthroughs, the event showcases the latest advancements in cancer science and medicine, driving collaboration and transforming lives.

Come stop by the Merck Booth #2036 and see some of our latest innovations:

• Enhanced TEER Measurements with Millicell^® ERS 3.0 Digital Voltohmmeter
• Cast gels in <3 minutes with mPAGE^® LUX Casting System
• PURedit^® Cas9 Cytosine Base Editor Kits offering precision and flexibility for challenging edits
• Explore our immunoassay solutions with MILLIPLEX^® Multiplex Kits and Luminex^® Instrument
• AAW™ Automated Assay Workstation bringing flexible power to your lab
• PromoCell Primary Cell Culture System
• …and more!

HUB Organoids is now part of Merck - Visit HUB Organoids at Booth #1947.

Explore Related Technical Resources & Posters – and visit our staff for more information!

General Cancer Research:

• Together Against Cancer

Merck and HUB Organoid Poster Presentations at the meeting:

April 19, 2026 2pm-5pm

• Characterizing organoid maturation and disease progression through recombinant monoclonal antibodies - Poster Section 30 | Poster Board #13 | Poster # 743
• Patient-Derived Organoid Biobanks Preserve Tumor Heterogenity and Molecular Signatures - Poster Section 28 | Poster Board #17 | Poster #701
• Patient-Derived Organoids: Insights into Cancer Evolution and Drug Resistance - Poster Section 28 | Poster Board #15 | Poster #699

April 20, 2026 2pm-5pm

• Robust multiplex cytokine profiling in second-generation humanized NOG mice using a 41-plex humanized mouse immune panel: Cross-donor validation and implications for oncology studies - Poster Section 27 | Poster Board #13 | Poster #3383
• Next-Generation FemtoQuest™ system enables dual-analyte ultrasensitive quantification of active and total HGF in melanoma plasma samples - Poster Section 24 | Poster Board #29 | Poster #3322
• A patient-derived organoid screening platform for evaluating KRAS inhibitor efficacy - Poster Section 19 | Poster Board #22 | Poster #3187
• Modeling chemotherapy persistence in colorectal cancer using patient-derived organoids - Poster Section 17 | Poster Board #19 | Poster #3119
• Preserving predictive power with minimal PDOs: Accelerated drug testing for personalized therapy in metastatic CRC - Poster Section 43 | Poster Board #22 | Poster #2515

April 21, 2026 2pm-5pm

• Exploring biomarker profiles in canine oncology using multiplex immunoassays - Poster Section 45 | Poster Board #21 | Poster #6588
• Assessment of multiplexed human and mouse cytokines in humanized mouse samples - Poster Section 45 | Poster Board #3 | Poster #6570
• An image-based approach to visualize ADC internalization and cytotoxicity in patient-derived organoids - Poster Section 12 | Poster Board #18 | Poster #5702
• A robust organoid-based platform for high-throughput screening and drug discovery - Poster Section 39 | Poster Board #4 | Poster #6404
• Organoid-T cell co-cultures: A robust platform for bispecific antibody immunotherapy development - Poster Section 6 | Poster Board #16 | Poster #5544

April 22, 2026 9am-12pm

• Automated multiplex profiling of human cytokines and autoantibodies using an Automated Assay Workstation - Poster Section 38 | Poster Board #23 | Poster #7669

Merck In the News

• Merck Acquires HUB Organoids Holding B.V., Expands Next-Gen Portfolio
• Merck Partners with Opentrons Labworks, Inc., supporting Lab of the Future
• Merck Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies
• Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies